肝动脉栓塞化疗联合体部立体定向放射治疗原发性肝癌的近期疗效分析

TACE combined with SBRT in the treatmeng of primary liver cancer

目的探讨肝动脉介入化疗(TACE)联合体部立体定向放射治疗(SBRT)原发性肝癌的近期疗效和毒副作用。方法对收治的PS评分≥2分的原发性肝癌患者58例予以TACE联合陀螺旋转式钴60SBRT治疗,随访观察患者疗效及毒副反应。结果 58例患者中完全缓解10例(17.24%),部分缓解21例(36.21%),稳定20例(34.48%),进展7例(12.07%)。总有效率为53.45%。1年局部控制率为36.21%,1年总生存率为62.07%。结论 TACE联合SBRT治疗原发性肝癌的近期疗效好,毒副作用低,远期疗效需进一步观察。

Objective To explore the recent curative efficacies and adverse responses of the transeatheter hepatic arterial chemomembolization （TACE）combined with stereotactic radiotherapy （SBRT） in the treatment of pa- tients with primary liver cancer. Methods Fifty-eight patients with primary liver cancer who had physical status score ≥2 were given TACE combined with gyro knife Co60 SBRT. All patients were followed up to observe curative effects and adverse responses. Results Total 58 patients had received the treatment. Ten patients（ 17.24% ） reached com- plete response, 21 patients（36. 21% ） partial response, 20（34. 48% ） stable disease and 7 （12. 07% ） disease pro- gression. The overall objective rate was 53.45% , one year local control rate 36. 21% and 1 year overall survival rate 62.07%. Conclusion The TACE combined with SBRT in the treatmeng of primary liver cancer displayed good re- cent curative efficacies, but low response rate of side effects. The long-term efficacies deserve further observation.